High-dose deferoxamine treatment [intravenous] for thalassaemia patients with cardiac complications
Voir/ Ouvrir
Résumé
As a means to manage cardiac conditions, we determined the effects of high-dose intravenous [IV] deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours [maximum 5 g] for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment. Visual and auditory examinations were done to detect any side-effects. After treatment, cardiovascular symptoms decreased considerably and systolic function showed significant improvement, but there was no significant effect on diastolic function, electro-cardiography and physical findings. There were no significant side-effects reportedCitation
Ghader, F.R., Kousarian, M. & Farzin, D. (2007). High-dose deferoxamine treatment [intravenous] for thalassaemia patients with cardiac complications. EMHJ - Eastern Mediterranean Health Journal, 13 (5), 1053-1059, 2007 https://iris.who.int/handle/10665/117346